The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Valenti, Maria Teresa ^a   Bertoldo, Francesco ^a   Dalle Carbonare, Luca ^a   Azzarello, Giuseppe ^b   Zenari, Sonia ^a   Zanatta, Mirko ^a   Balducci, Elena ^b   Vinante, Orazio ^b   Lo Cascio, Vincenzo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Noale Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ACCURACY; ARTICLE; BREAST CANCER; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GENE TARGETING; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HUMANS; MALE; PROSTATIC NEOPLASMS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33744795451     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-49     Document Type: Article

References (41)

1. Edwards DR, Denhardt DT: A study of mitochondrial and nuclear transcription with cloned cDNA probes. Changes in the relative abundance of mitochondrial transcripts after stimulation of quiescent mouse fibroblasts. Exp Cell Res 1985, 157:127-143.
2. Lim YC, Desta Z, Flockhart DA, Skaar TC: Endoxifen has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005, 55:471-8.
3. Ullmannova V, Haskovec C: The use of housekeeping genes (HKG) as an internal control in the detection of gene expression by quantitative real time RT-PCR. Folia Biol 2003, 49:211-6.
4. Oliveira JG, Prados RZ, Guedes AC, Ferreira PC, Kroon EG: The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase is inappropriate as internal control in comparative studies between skin tissue and cultured skin fibroblasts using Northern blot analysis. Arch Dermatol Res 1999, 291:659-661.
5. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-193.
6. Barroso I, Benito B, Garci-Jimenez C, Hernandez A, Obregon MJ, Santisteban P: Norepinephrine, tri-iodothyronine and insulin upregulate glyceraldehyde-3-phosphate dehydrogenase mRNA during Brown adipocyte differentiation. Eur J Endocrinol 1999, 141:169-179.
7. Desprez PY, Poujol D, Saez S: Glyceraldehyde-3-phosphate dehydrogenase gene expression in two malignant human mammary epithelial cell lines: BT-20 and MCF-7 regulation of gene expression by 1,25 dihydroxyvitamin D3 (1,25-(OH)2D3). Cancer Lett 1992, 64:219-244.
8. Revillion F, Pawlowski V, Hornez L, Peyrat JP: Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer 2000, 36:1038-1042.
9. Chang TJ, Juan CC, Yin PH, Chi CW, Tsay HJ: Up-regulation of beta-actin, cyclophilin and GAPDH in NISI rat hepatoma. Oncol Rep 1998, 5:469-471.
10. Bhatia P, Taylor WR, Greenberg AH, Wright JA. Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. Anal Biochem 1994, 216:223-226.
11. Ripple MO, Wilding G: Alteration of glyceraldehyde-3-phosphate dehydrogenase activity and messenger RNA content by androgen in human prostate carcinoma cells. Cancer Res 1995, 55:4234-4236.
12. Varghese S, Canalis E: Alendronate stimulates Collagenase 3 expression in osteoblasts by posttranscriptional mechanisms. J Bone Miner Res 2000, 15:2345-2351.
13. Dalle Carbonare L, Valenti MT, Azzarello G, Balducci E, Crepaldi G, Realdi G, Vinante O, Giannini S. Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Mol Cell Endocrinol 2005, 240:23-31.
14. Fleish H: Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin Othop 1987, 217:72-78.
15. Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonate, osteoclast, and bone. Calcif Tissue Int 1991, 49:407-415.
16. Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonates treatment inhibits the growth of prostate cancer cells. Cancer Res 2001, 61:2602-2608.
17. Boisser S, Magnetto S, Frapport L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized bone extracellular matrices. Cancer Res 1997, 57:3890-3894.
18. Brown JE, Neville-Webbe H, Coleman RE: The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 2004, 11:207-24.
19. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997, 98:665-72.
20. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR, Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003, 88:1971-1978.
21. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanism of action of bisphosphonates. Cancer 2000, 88:2961-297.
22. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC: Bisphosphonates Pamidronate and Zoledronic acid Stimulates osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291:680-686.
23. Green JR: Bisphosphonates: preclinical review. Oncologist 2004, 9:3-13.
24. Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000, 15:2211-2221.
25. Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res 1996, 6:986-994.
26. Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A: Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochemical J 2004, 384:591-598.
27. Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE: Modulation of TNF-alpha gene expression by IFN-gamma and Pamidronate in murine macrophages: regulation by STATI-dependent pathways. J Immunol 2005, 174:1801-1810.
28. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AB: The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activing TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004, 19:147-154.
29. Myoung H, Park JY, Choung PH: Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. J Periodontal Res 2001, 36:244-251.
30. Kim YH, Kim GS, Jeong-Hwa B: Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 2002, 34:145-151.
31. Nishida S, Tsubaki M, Hoshino M, Namimatsu A. Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K: Nitrogen-containing bisphosphonates, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 2005, 328:91-97.
32. 3) on Parathyroid Hormone-Related Protein Expression in Human osteoblastic cells. J Bone Miner Res 2003, 18:78-87.
33. Yasui T, Fujita K, Sasaki S, Iguchi M, Hirota S, Nomura S, Azuma Y, Ohta T, Kohri K: Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrp) in the rat kidney. Urol Res 1998, 26:355-360.
34. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I: Sequence and schedule-Dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113:364-371.
35. Van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003, 33:805-11.
36. Xing C, LaPorte JR, Barbay JK, Myers AG: Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proc Natl Acad Sci USA 2004, 101:5862-5866.
37. Sirover MA: New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1999, 1432:159-184.
38. Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE: A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol 2001, 59:367-74.
39. Zheng L, Roeder RG, Luo Y: S phase activation of the histone H26 promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003, 114:255-266.
40. Appelskog IB, Ammerpohl O, Svechnikova IG, Lui WO, Almqvist PM, Ekstrom TJ: Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA Expression in glioma cells. Int J Oncol 2004, 24:1419-25.
41. Tatton WG, Chalmers-Redman RM, Elstner M, Leesch W, Jagodzinski FB, Stupak DP, Sugrue MM, Tatton NA: Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signalling. J Neural Transm 2000, 60:77-100.